BenevolentAI Past Earnings Performance

Past criteria checks 0/6

BenevolentAI's earnings have been declining at an average annual rate of -13.5%, while the Pharmaceuticals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 11.3% per year.

Key information

-13.5%

Earnings growth rate

125.5%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate11.3%
Return on equity-67.2%
Net Margin-863.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How BenevolentAI makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2XA Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 237-632357
30 Sep 239-611964
30 Jun 2311-591470
31 Mar 2311-1126971
31 Dec 2211-16412572
30 Sep 229-18614169
30 Jun 228-20815766
31 Mar 226-15810661
31 Dec 215-1085657
31 Dec 207-555220
31 Dec 195-484121
31 Dec 187-27400

Quality Earnings: 2XA is currently unprofitable.

Growing Profit Margin: 2XA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2XA is unprofitable, and losses have increased over the past 5 years at a rate of 13.5% per year.

Accelerating Growth: Unable to compare 2XA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2XA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).


Return on Equity

High ROE: 2XA has a negative Return on Equity (-67.16%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies